A candidate tumor suppressor HtrA1 is downregulated in ovarian cancer

被引:146
作者
Chien, J
Staub, J
Hu, SI
Erickson-Johnson, MR
Couch, FJ
Smith, DI
Crowl, RM
Kaufmann, SH
Shridhar, V
机构
[1] Mayo Clin & Mayo Fdn, Div Expt Pathol, Dept Expt Pathol, Rochester, MN 55905 USA
[2] Mayo Clin Canc Ctr, Rochester, MN 55905 USA
[3] Novartis Pharmaceut, Arthrit Biol Unit, E Hanover, NJ 07936 USA
[4] Mayo Clin & Mayo Fdn, Dept Oncol, Rochester, MN 55905 USA
关键词
serine protease; HtrA; ovarian cancer; down-regulation; loss of heterozygosity;
D O I
10.1038/sj.onc.1207271
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
We report here that HtrA1, a candidate tumor suppressor, is downregulated in ovarian cancer. Expression of HtrA1 is downregulated in five of seven ovarian cancer cell lines. In total, 59% of primary ovarian tumors have either a complete absence or markedly reduced levels of HtrA1 expression compared to the brushings of ovarian surface epithelium. Primary ovarian tumors show high frequencies of loss of an allele at microsatellite markers near htrA1 locus on 10q26. Downregulation of HtrA1 in SKOV3 by antisense transfection promotes anchorage-independent growth, while exogenous expression of HtrA1 in OV202 induces cell death. HtrA1-induced cell death is not inhibited by the broad caspase inhibitor, zVAD(O-Me) fmk, but instead reflects serine protease activity associated with HtrA1. These observations raise the possibility of HtrA1 as a candidate tumor suppressor involved in promoting serine-protease-mediated cell death and that downregulation of HtrA1 in ovarian cancer may contribute to malignant phenotype.
引用
收藏
页码:1636 / 1644
页数:9
相关论文
共 32 条
  • [1] Albarosa R, 1996, AM J HUM GENET, V58, P1260
  • [2] The HtrA1 serine protease is down-regulated during human melanoma progression and represses growth of metastatic melanoma cells
    Baldi, A
    De Luca, A
    Morini, M
    Battista, T
    Felsani, A
    Baldi, F
    Catricalà, C
    Amantea, A
    Noonan, DM
    Albini, A
    Natali, PG
    Lombardi, D
    Paggi, MG
    [J]. ONCOGENE, 2002, 21 (43) : 6684 - 6688
  • [3] The HtrA family of proteases: Implications for protein composition and cell fate
    Clausen, T
    Southan, C
    Ehrmann, M
    [J]. MOLECULAR CELL, 2002, 10 (03) : 443 - 455
  • [4] Biological characterization of human epithelial ovarian carcinoma cells in primary culture: The insulin-like growth factor system
    Conover, CA
    Hartmann, LC
    Bradley, S
    Stalboerger, P
    Klee, GC
    Kalli, KR
    Jenkins, RB
    [J]. EXPERIMENTAL CELL RESEARCH, 1998, 238 (02) : 439 - 449
  • [5] Analysis of losses of heterozygosity of the candidate tumour suppressor gene DMBT1 in melanoma resection specimens
    Deichmann, M
    Mollenhauer, J
    Helmke, B
    Thome, M
    Hartschuh, W
    Poustka, A
    Näher, H
    [J]. ONCOLOGY, 2002, 63 (02) : 166 - 172
  • [6] ENOMOTO T, 1991, AM J PATHOL, V139, P777
  • [7] Inhibition of human caspases by peptide-based and macromolecular inhibitors
    Garcia-Calvo, M
    Peterson, EP
    Leiting, B
    Ruel, R
    Nicholson, DW
    Thornberry, NA
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 1998, 273 (49) : 32608 - 32613
  • [8] Cancer statistics, 2000
    Greenlee, RT
    Murray, T
    Bolden, S
    Wingo, PA
    [J]. CA-A CANCER JOURNAL FOR CLINICIANS, 2000, 50 (01) : 7 - 33
  • [9] Identification of Omi/HtrA-2 as a mitochondrial apoptotic serine protease that disrupts inhibitor of apoptosis protein-caspase interaction
    Hegde, R
    Srinivasula, SM
    Zhang, ZJ
    Wassell, R
    Mukattash, R
    Cilenti, L
    DuBois, G
    Lazebnik, Y
    Zervos, AS
    Fernandes-Alnemri, T
    Alnemri, ES
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 2002, 277 (01) : 432 - 438
  • [10] Human HtrA, an evolutionarily conserved serine protease identified as a differentially expressed gene product in osteoarthritic cartilage
    Hu, SI
    Carozza, M
    Klein, M
    Nantermet, P
    Luk, D
    Crowl, RM
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 1998, 273 (51) : 34406 - 34412